æ±åå»ç§è¬ç§å¤§å¦ç é¢ã¯2æ25æ¥ãæ°åã³ããã¦ã¤ã«ã¹ã®åºç¤ç¥èã¨ææ対çãã¾ã¨ããPDFå½¢å¼ã®ãã³ãããã¯ãåç é¢ã®Webãµã¤ãä¸ã§å ¬éãããããã¨ãã±ããããã¹ã¯ã®æ£ããçãæ¹ãæã®æ´ãæ¹ãªã©ã«ã¤ãã¦è§£èª¬ãã¦ãããWebãã©ã¦ã¶ã§èªããã»ããç¡æã§ãã¦ã³ãã¼ããã§ããã æ±åå»ç§è¬ç§å¤§å¦ããæ°åã³ããã¦ã¤ã«ã¹ææç ï½å¸æ°åãææäºé²ãã³ãããã¯ããã¤ã³ã¿ã¼ãããä¸ã§å ¬é ãæ°åã³ããã¦ã¤ã«ã¹ææç ï½å¸æ°åãææäºé²ãã³ãããã¯ãã¯è¨20ãã¼ã¸ã§æ§æã2020å¹´2ææç¹ã®æ å ±ãå ã«ãæ°åã³ããã¦ã¤ã«ã¹ææç(COVID-19)ã®çç¶ã®ç¹å¾´ãææã®ä»æ¹ããæ¿åæ¥è§¦ãã®å®ç¾©ã¨ãã£ãåºç¤ç¥èãããããããè¨èã§ç´¹ä»ãã¦ããã 家åºã§ã§ããææ対çã®åºæ¬ã¯ããã¾ããªææ´ããããæ£ãããã¹ã¯ã®ä½¿ç¨ãããçç¶ãããã¨ãã¯å¤åºãæ§ãããã¨ããææã®ãªã¹ã¯ãä¸ãã対çã¨ãã¦ããããã¨ãã±ãããå®ããã
æ°åã³ããã¦ã¤ã«ã¹ã«ããææçã§ãåçå´åçãªã©ã¯13æ¥ãç¥å¥å·çã®80代ã®å¥³æ§ãææããæ»äº¡ããã¨çºè¡¨ãããææè ã®æ»äº¡ã¯å½å ã§åãã¦ãã¾ãããã®å¥³æ§ä»¥å¤ã«ãè¨3人ã®ææãæ°ãã«ç¢ºèªããããããããæè¿ãä¸å½ã¸ã®æ¸¡èªæ´ãèºçæ£è ã¨ã®æ確ãªæ¥è§¦ã¯ç¢ºèªã§ããªãã£ãã¨ãããåå´çã¯ææçµè·¯ã調ã¹ã¦ããã åå´çãªã©ã«ããã¨ãç¥å¥å·çã®å¥³æ§ã¯1æ22æ¥ã«ä½ã®ã ãããè¦ãã28æ¥ã«å»çæ©é¢ãå診ã2æ1æ¥ã®åå診ã§èºçã®è¨ºæãåãã¦å ¥é¢ããã6æ¥ã«æçå¤ã使ã£ãæ²»çãåãããå¼å¸ç¶æ ãæªåãã13æ¥ã«æ»äº¡ã確èªãããã12æ¥ã«ã¦ã¤ã«ã¹æ¤æ»ããã¦ãããæ»äº¡å¾ã«é½æ§ã¨ç¢ºèªãããã¨ãããææã¨æ»äº¡ã¨ã®å æé¢ä¿ã¯èª¿æ»ä¸ã ãã女æ§ã«æè¿ã®æ¸¡èªæ´ã¯ãªãã£ãã
ãã®æ°æ¥ã§ä¸æ°ã«å¦è¡èªã«æ°åã³ããã¦ã¤ã«ã¹ææçã«é¢ããè«æãæ²è¼ããå§ãã¾ããã ææçã®ã¢ã¦ããã¬ã¤ã¯ã®éã®è«æåã®ã¹ãã¼ãã¯å¹´ã æ©ããªã£ã¦ãã¾ãããã¤ãã«ããã¾ã§æ¥ããã¨æãã»ã©ã®ã¹ãã¼ãã¨ã¯ãªãªãã£ã§ãã ãã®ä¸ã§è¨åºçç¶ã«ã¤ãã¦è©³ç´°ãè¨è¼ããããã®ãããã¾ããã ããã¾ã§ã«æããã«ãªã£ã¦ããªãã£ãæ å ±ãããã¤ãããã¾ãã®ã§ãç´¹ä»ãã¾ãã ããå°éçãªå 容ãå«ã¾ãã¾ãããã§ããã ãåãããããè¨è¼ãã¾ããã æ£è ã®ç¹å¾´ 2020å¹´1æ2æ¥ã¾ã§ã«æ°åã³ããã¦ã¤ã«ã¹ææçã¨è¨ºæããã41人ã«é¢ãã¦ã ã»73ï¼ ãç·æ§ ã»32ï¼ ãä½ããã®æç ãããï¼ç³å°¿ç 20%ãé«è¡å§15ï¼ ãå¿è¡ç®¡ç¾æ£15ï¼ ãªã©ï¼ ã»å¹´é½¢ã®ä¸å¤®å¤ã¯49.0æ³(ååä½ç¯å² 41-58æ³) ã»66%ã«è¯åæµ·é®®å¸å ´ã¸ã®ä½ããã®æ¥è§¦ããã£ã ã»41äººå ¨å¡ã«èºçãã ã»åä½µçã¨ãã¦æ¥æ§å¼å¸ä¿è¿«çå群29%ãã¦ã¤ã«ã¹è¡ç15%ãæ¥æ§
ææ°ã®å»å¦æ å ±ãå¯ããããå½å å¤ã®å»å¦èªã»å»å¦ä¼ã大å¦ãå ¬çå£ä½ã®ç 究çºè¡¨ããã¨ã«ä½æã»é ä¿¡ãããå»çã»å¥åº·ãã¥ã¼ã¹é ä¿¡ãµã¤ãã ãã«ã¹ãã¼ãã¥ã¼ã¹ ææ°ã®å»å¦æ å ±ãå¯ããããå½å å¤ã®å»å¦èªã»å»å¦ä¼ã大å¦ãå ¬çå£ä½ã®ç 究çºè¡¨ããã¨ã«ä½æã»é ä¿¡ãããå»çã»å¥åº·ãã¥ã¼ã¹ã§ããå»çåéã ãã§ãªãéåãé£çæ´»ãªã©å¥åº·ã¨å¯æ¥ã«ãããããã«ã¹ã±ã¢è¨äºãç´¹ä»ãã¾ãã詳ããå©ç¨è¦å®ã¯ãã¡ããã覧ãã ããã ããã¯ãã³ãã¼ä¸è¦§ ã¤ã³ãã«ã¨ã³ã¶ã®ã¯ã¯ãã³æ¥ç¨®ã¯æ©ãã« ç±³ç¾ç 対çã»ã³ã¿ã¼ï¼CDCï¼ã¯ãååçã§ã®ç¶æ³ãéã¿ãã¨ä»ã·ã¼ãºã³ã¯ååçã§ãã¤ã³ãã«ã¨ã³ã¶ã®æµè¡ãæ©ã¾ãã¨èããããç´ã¡ã«äºé²æ¥ç¨®ãåããã¹ãã§ããã¨ããè¦åããCDCçºè¡ã®ãMorbidity and Mortality Weekly Reportã10æ11æ¥å·ã«ããã¦çºä¿¡ããã ã¤ã³ãã«ã¨ã³ã¶ã«é¢ãããã®ææ°æ å ±ãå·çããCDCã®Scot
å°ç¨ãããã®ã¢ã«ããé»ç£æ°çæ³ã§ãã¢ã«ããã¤ãã¼ç æ£è ã®èªç¥ããã©ã¼ãã³ã¹ãåä¸ NEUROEM THERAPEUTICS, INC. ï¼ã¢ã¡ãªã«ã®ç 究è ãç¬èªã®å°ç¨ãããã®ã¢ãç¨ããçµé èé»ç£æ°çæ³ã®è¨åºå®é¨ã«ããã¦ãã¢ã«ããã¤ãã¼ç æ£è ã®èªç¥ããã©ã¼ãã³ã¹ãåä¸ãããã¨ãæããã«......ï¼ ç±³åãããªã大å¦ã§ææãåããçµé¨ãæã¤ã²ã¤ãªã¼ã»ã¢ã¬ã³ããã·ã¥å士ã¯ãç±³ã¢ãªã¾ãå·ãã§ããã¯ã¹ã§å»çæ©å¨ä¼ç¤¾ããã¥ã¼ãEMã»ã»ã©ãã¥ã¼ãã£ãã¯ã¹ããåµè¨ããã¢ã«ããã¤ãã¼ç ãªã©ã®ç¥çµå¤æ§ç¾æ£ã«å¯¾ããæ°ããªæ²»çæ³ã¨ãã¦çµé èé»ç£æ°çæ³ï¼TEMTï¼ã®ç 究éçºã«åãçµãã§ããã ããã¥ã¼ãEMã»ã»ã©ãã¥ã¼ãã£ãã¯ã¹ãã¯ã2019å¹´9æ17æ¥ãç¬èªã®å°ç¨ãããã®ã¢ãã¡ã¢ã«EMTMããç¨ããçµé èé»ç£æ°çæ³ã®è¨åºå®é¨ã«ããã¦ãã¢ã«ããã¤ãã¼ç æ£è ã®èªç¥ããã©ã¼ãã³ã¹ãåä¸ãããã¨ãæããã«ããã ä¸é£ã®
ç³ç ´ç·çã«ãâæ¿æ²»ã¨ã«ãâçææµ®ä¸ãèªæ°ã»è£éåé¡ã®è§£æã¯ï¼åçºãã大å¦ææãã¾ãã¯èªåã®èª¿æ»ãããå ±éç¹éã 10æ1æ¥ã«ã¹ã¿ã¼ãããç³ç ´æ°å é£ã解æ£ãå·¡ã£ã¦ã®ç·çã®çºè¨ä¿®æ£ããææãæ©ã¾ã£ããã¨ã«ã¤ãã¦ãâè£â¦
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}